Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Beam Therapeutics reported Q1 2026 revenue of $31.7 million, up significantly from the prior year, while narrowing its net loss to $0.91 per share. The company ended the quarter with $1.2 billion in cash, which is expected to fund operations into mid-2029. Pipeline progress included the publication of Risto-cel data in the New England Journal of Medicine and a reaffirmed target to submit a BLA for the sickle cell disease treatment by year-end 2026. The company also selected 60 mg as the optimal biological dose for BEAM-302 in alpha-1 antitrypsin deficiency and plans to initiate a pivotal cohort in the second half of the year.
Key figures
- Revenue
- 31738000
- Cash runway
- mid-2029
- Ga expenses
- 34429000
- Rd expenses
- 104524000
- Cash position
- 1200000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.